H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 19.68 HKD -1.6%
Market Cap: 17.2B HKD

P/E
Price to Earnings

-53.4
Current
-14.6
Median
20.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-53.4
=
Market Cap
17.3B HKD
/
Net Income
-42m USD
Earnings Growth PEG
HK
H
HUTCHMED (China) Ltd
HKEX:13
Average P/E: 25.7
Negative Multiple: -53.4
6%
N/A
US
Eli Lilly and Co
NYSE:LLY
65
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.7
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
19%
1
CH
Roche Holding AG
SIX:ROG
17.3
16%
1.1
CH
Novartis AG
SIX:NOVN
17.8
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
20.2
28%
0.7

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-39.9
2-Years Forward
P/E
6
3-Years Forward
P/E
18.3